SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 57.04-1.8%3:48 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (9243)10/1/2003 9:54:25 AM
From: Icebrg  Read Replies (2) of 52153
 
>>But maybe those that said that combining an EGFR drug that halts cells in the G1 phase doesn't make sense when combined with a chemo drug that requires that the cell be in another phase (S or M) for efficacy.>>

I have never fully understood that argument. Maybe because of my ignorance. But my concern with the theory is that, as the cancer evidently advances, there must be a fair number of cancer cells that manages to complete the full loop. Why is their progress not halted by Iressa/Tarceva and/or the chemo used.

Erik
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News